A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration

    Not Recruiting
  • participants needed
  • sponsor
    Guangdong Hengrui Pharmaceutical Co., Ltd
Updated on 27 November 2022
Accepts healthy volunteers


This is a first-in-human study that will investigate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of HRS-2261 using a double blind, placebo controlled, randomized study design. The influence of food on the pharmacokinetics of HRS-2261 and the effects of HRS-2261 on CYP3A4 metabolic enzymes will also be investigated.

Condition Chronic Cough
Treatment HRS-2261 tablet、placebo
Clinical Study IdentifierNCT05274516
SponsorGuangdong Hengrui Pharmaceutical Co., Ltd
Last Modified on27 November 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note